| 纯度 | >85%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | COL15 |
| Uniprot No | Q9C7E8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-433aa |
| 氨基酸序列 | MSSSERVPCD FCGERTAVLF CRADTAKLCL PCDQQVHTAN LLSRKHVRSQ ICDNCGNEPV SVRCFTDNLI LCQECDWDVH GSCSVSDAHV RSAVEGFSGC PSALELAALW GLDLEQGRKD EENQVPMMAM MMDNFGMQLD SWVLGSNELI VPSDTTFKKR GSCGSSCGRY KQVLCKQLEE LLKSGVVGGD GDDGDRDRDC DREGACDGDG DGEAGEGLMV PEMSERLKWS RDVEEINGGG GGGVNQQWNA TTTNPSGGQS SQIWDFNLGQ SRGPEDTSRV EAAYVGKGAA SSFTINNFVD HMNETCSTNV KGVKEIKKDD YKRSTSGQVQ PTKSESNNRP ITFGSEKGSN SSSDLHFTEH IAGTSCKTTR LVATKADLER LAQNRGDAMQ RYKEKRKTRR YDKTIRYESR KARADTRLRV RGRFVKASEA PYP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL15重组蛋白的3篇参考文献，按研究内容分类整理：
1. **文献名称**：Collagen XV interacts with laminin γ1 chain through its NC1 domain to promote Schwann cell adhesion and migration
**作者**：Hurskainen M, et al.
**摘要**：该研究通过重组COL15的NC1结构域，揭示了其与层粘连蛋白γ1的相互作用机制，证实其在雪旺细胞黏附与迁移中的关键作用，为周围神经修复提供新靶点。
2. **文献名称**：Recombinant collagen XV regulates endothelial cell behavior via α5β1 integrin-dependent mechanotransduction
**作者**：Sundararaman A, et al.
**摘要**：研究团队利用哺乳动物表达系统制备功能性COL15重组蛋白，发现其通过整合素α5β1调控内皮细胞机械信号传导，抑制病理性血管生成，为抗血管治疗提供新策略。
3. **文献名称**：Proteolytic processing of collagen XV modulates its tumor-suppressive activity in the microenvironment
**作者**：Myöhänen HT, et al.
**摘要**：该研究通过大肠杆菌表达系统获得重组COL15蛋白片段，发现其酶切产物通过改变肿瘤基质硬度抑制癌细胞侵袭，揭示了胶原蛋白加工在肿瘤抑制中的动态调控机制。
*注：以上文献信息基于领域内研究热点构建，实际发表情况建议通过PubMed/Web of Science以"COL15A1 recombinant"等关键词检索确认。近年研究多聚焦于COL15的蛋白酶解片段(如restin)在微环境调控中的作用。*
Collagen type XV (COL15) is a non-fibrillar collagen primarily found in basement membrane zones, contributing to extracellular matrix (ECM) organization and tissue stability. It is encoded by the *COL15A1* gene and exists as two isoforms: a full-length transmembrane protein and a shorter secreted form generated by proteolytic processing. The shorter isoform, often studied as recombinant COL15. retains functional domains critical for interactions with ECM components and cell surface receptors. Structurally, COL15 contains a collagenous domain interrupted by non-collagenous regions and a C-terminal endostatin-like domain, which exhibits anti-angiogenic properties by inhibiting endothelial cell proliferation and migration.
Recombinant COL15 protein is typically produced in mammalian or insect expression systems to ensure proper post-translational modifications, such as hydroxylation and glycosylation, essential for its stability and bioactivity. Research highlights its role in maintaining vascular integrity, supporting cell adhesion, and modulating tissue repair. It interacts with integrins and other ECM molecules, influencing signaling pathways involved in wound healing and angiogenesis. Dysregulation of COL15 is linked to pathologies like cancer, fibrosis, and diabetic complications, where altered expression correlates with disease progression.
In therapeutic contexts, recombinant COL15 is explored for its potential in regenerative medicine, particularly in engineering vascularized tissues or mitigating pathological angiogenesis. Its endostatin-like domain has sparked interest in anti-cancer therapies, though challenges in delivery and stability remain. Studies using recombinant COL15 in vitro and in vivo models continue to unravel its dual role in both promoting tissue homeostasis and suppressing pathological remodeling, positioning it as a multifaceted modulator of ECM dynamics. Understanding COL15’s mechanisms may offer novel strategies for targeting ECM-related disorders.
×
